8th Jun 2016 08:57
LONDON (Alliance News) - GlaxoSmithKline PLC presented positive phase III data for Benlysta in the treatment of highly active systemic lupus erythematosus at the Annual European Congress of Rheumatology in London.
The data showed that patients treated with Benlysta experienced a significantly greater response to the treatment combined with standard of care, compared to a placebo plus standard of care.
This is the third successful phase III study of the treatment in systemic lupus erythematosus, Glaxo said.
"One of the major challenges facing clinicians managing patients with SLE is to predict the disease course, as it fluctuates and varies greatly between individuals, from relatively benign to rapidly progressive and even fatal," said Andrea Doria of the University of Padua, Italy.
"Research suggests that controlling this disease activity plays an important role in improving patient outcomes. The range of clinical benefits seen with Benlysta in this sub-set of patients with more active lupus provides valuable insights for clinicians about disease characteristics that may help inform the potential response to treatment and improve certain outcomes for patients living with this debilitating disease," Doria added.
Shares in GlaxoSmithKline were down 0.7% at 1,452.00 pence Wednesday morning.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright 2016 Alliance News Limited. All Rights Reserved.
Related Shares:
Glaxosmithkline